79 related articles for article (PubMed ID: 12015696)
1. Will genetic testing alter the management of disease caused by infectious agents? A cost-effectiveness analysis of gene-testing strategies for prevention of rheumatic Fever.
King CH; Fischler DF; Gerkin RD
Clin Infect Dis; 2002 Jun; 34(11):1491-9. PubMed ID: 12015696
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of different treatment strategies with intrapartum antibiotic prophylaxis to prevent early-onset group B streptococcal disease.
Akker-van Marle ME; Rijnders ME; Dommelen P; Fekkes M; Wouwe JP; Amelink-Verburg MP; Verkerk PH
BJOG; 2005 Jun; 112(6):820-6. PubMed ID: 15924544
[TBL] [Abstract][Full Text] [Related]
3. Primary prevention of acute rheumatic fever and rheumatic heart disease with penicillin in South African children with pharyngitis: a cost-effectiveness analysis.
Irlam J; Mayosi BM; Engel M; Gaziano TA
Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):343-51. PubMed ID: 23652737
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and management of pharyngitis in a pediatric population based on cost-effectiveness and projected health outcomes.
Van Howe RS; Kusnier LP
Pediatrics; 2006 Mar; 117(3):609-19. PubMed ID: 16510638
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care.
Mrus JM; Tsevat J
Med Decis Making; 2004; 24(1):30-9. PubMed ID: 15005952
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of strategies that are intended to prevent kernicterus in newborn infants.
Suresh GK; Clark RE
Pediatrics; 2004 Oct; 114(4):917-24. PubMed ID: 15466085
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of herpes simplex virus testing and treatment strategies in febrile neonates.
Caviness AC; Demmler GJ; Swint JM; Cantor SB
Arch Pediatr Adolesc Med; 2008 Jul; 162(7):665-74. PubMed ID: 18606938
[TBL] [Abstract][Full Text] [Related]
8. Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis.
Smith KJ; Monsef BS; Ragni MV
Thromb Haemost; 2008 Sep; 100(3):447-52. PubMed ID: 18766261
[TBL] [Abstract][Full Text] [Related]
9. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics.
Gerber MA; Baltimore RS; Eaton CB; Gewitz M; Rowley AH; Shulman ST; Taubert KA
Circulation; 2009 Mar; 119(11):1541-51. PubMed ID: 19246689
[TBL] [Abstract][Full Text] [Related]
10. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)].
Hagen A; Hessabi HK; Gorenoi V; Schönermark MP
Gesundheitswesen; 2008 Jan; 70(1):18-27. PubMed ID: 18273760
[TBL] [Abstract][Full Text] [Related]
11. Analysis of costs of acute rheumatic fever and rheumatic heart disease in Auckland.
North DA; Heynes RA; Lennon DR; Neutze J
N Z Med J; 1993 Sep; 106(964):400-3. PubMed ID: 8377955
[TBL] [Abstract][Full Text] [Related]
12. Is antibiotic prophylaxis for bacterial endocarditis cost-effective?
Agha Z; Lofgren RP; VanRuiswyk JV
Med Decis Making; 2005; 25(3):308-20. PubMed ID: 15951458
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.
Lin OS; Keeffe EB; Sanders GD; Owens DK
Aliment Pharmacol Ther; 2004 Jun; 19(11):1159-72. PubMed ID: 15153169
[TBL] [Abstract][Full Text] [Related]
14. Is primary prevention of rheumatic fever the missing link in the control of rheumatic heart disease in Africa?
Karthikeyan G; Mayosi BM
Circulation; 2009 Aug; 120(8):709-13. PubMed ID: 19667233
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility of tuberculosis prevention among HIV-infected adults in Kampala, Uganda.
Shrestha RK; Mugisha B; Bunnell R; Mermin J; Odeke R; Madra P; Hitimana-Lukanika C; Adatu-Engwau F; Blandford JM
Int J Tuberc Lung Dis; 2007 Jul; 11(7):747-54. PubMed ID: 17609049
[TBL] [Abstract][Full Text] [Related]
16. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
17. Costs and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision analytic model.
Saab S; DeRosa V; Nieto J; Durazo F; Han S; Roth B
Am J Gastroenterol; 2003 Apr; 98(4):763-70. PubMed ID: 12738453
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands.
Wonderling D; Umans-Eckenhausen MA; Marks D; Defesche JC; Kastelein JJ; Thorogood M
Semin Vasc Med; 2004 Feb; 4(1):97-104. PubMed ID: 15199439
[TBL] [Abstract][Full Text] [Related]
19. A community-based rheumatic fever/rheumatic heart disease cohort: twelve-year experience.
Kumar R; Raizada A; Aggarwal AK; Ganguly NK
Indian Heart J; 2002; 54(1):54-8. PubMed ID: 11999089
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
